CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Men and women aged 45-75 years
Indication of colorectal cancer screening colonoscopy by treating physician
First-degree family history of CRC
Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
Other malignancies within 5 years
Known hereditary CRC syndromes (Lynch, FAP)